8-chloro-1-{4-[(cyclohexylisopropylamino)methyl]phenyl}-6-fluoro-4-oxo-7-(4-pyridin-2-ylpiperazine-1-yl)-1,4-dihydroquinoline-3-carboxylic acid | 866957-04-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-chloro-1-{4-[(cyclohexylisopropylamino)methyl]phenyl}-6-fluoro-4-oxo-7-(4-pyridin-2-ylpiperazine-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 8-Chloro-1-[4-[[cyclohexyl(propan-2-yl)amino]methyl]phenyl]-6-fluoro-4-oxo-7-(4-pyridin-2-ylpiperazin-1-yl)quinoline-3-carboxylic acid
• CAS: 866957-04-2
• 化学式: C₃₅H₃₉ClFN₅O₃
• 分子量: 632.178
• InChiKey: FDVWREPEABIKGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  45
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE DE QUINOLONE POUR LE TRAITEMENT DES TROUBLES HYPERPROLIFERATIFS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005097752A1

  公开（公告）日：2005-10-20

  Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

  公开和声明了式(I)的喹诺酮羧酸衍生物，其中Ar是可选择地取代的苯基、吡啶基或嘧啶基，取代基R1、R4、R10、R11、R19和R20如规范中定义，包含它们的药物组合物，以及在治疗癌症等高增殖性疾病中使用它们的方法。
• Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions
  申请人：Khire Uday

  公开号：US20070213339A1

  公开（公告）日：2007-09-13

  Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R 1 , R 4 , R 10 , R 11 , R 19 , and R 20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

  公开了式(I)的喹诺酮羧酸衍生物，其中Ar是可选择性地取代的苯基，吡啶基或嘧啶基，取代基R1，R4，R10，R11，R19和R20如规范中所定义，以及包含它们的制药组合物和在治疗增生性疾病如癌症中使用它们的方法。
• QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS
  申请人：Bayer Pharmaceuticals Corporation

  公开号：EP1732897A1

  公开（公告）日：2006-12-20